We have significant collaborative drug discovery programmes with Takeda Pharmaceuticals in advanced liver fibrosis and NASH and with Dompé farmaceutici to enable identification and engineering of new precision medicines against fibrosis and liver-associated cancers.
Collaboration and Licensing agreement to develop new anti-fibrotic therapies in inflammatory bowel disease (IBD)
This collaboration builds on our existing collaboration in advanced liver diseases and combines Engitix’s unique human extracellular matrix (ECM) platform with Takeda’s world-leading expertise in gastroenterology research and development (R&D) and commercialisation.
“Partnerships are central to our R&D strategy, forming collaborations anchored around novel scientific approaches in disease areas where patients’ needs are greatest. Engitix’s ECM platform will help accelerate the identification and validation of novel targets that will be valuable in our search for better therapies for all those affected by GI and liver diseases.”
Dr Gareth Hicks, Head of the GI Drug Discovery Unit at Takeda
Collaboration and Investment agreement to accelerate the clinical translation of fibrosis and solid tumours targets and discovery of precision engineered medicines.
The collaboration combines the power of Exscalate, Dompé’’s AI supercomputer structure-based drug design platform, and it’s drug discovery expertise with Engitix’s patient-centric ECM platform and deep understanding of the human ECM.
“Our mission is to improve people’s lives and we partner with the best groups to accelerate research that will bring new solutions to patients. Working together enables us to combine the power of Exscalate with Engitix’s deep understanding of the biology of fibrosis and solid tumours and the unique strength of its ECM platform. Our collaboration will enable us to accelerate the clinical translation of targets beyond our four key in-house therapeutic areas.”
Marcello Allegretti, CSO of Dompé farmaceutici
Licensing and Collaboration agreement to discover and develop novel therapeutics for advanced fibrotic liver diseases.
This collaboration combines the strengths of Engitix’s unique ECM platform with Takeda’s world-leading expertise in gastroenterology research and development and commercialisation.
“here is a vital need for new treatments that will positively impact the lives of patients with advanced liver diseases. Engitix’s ECM platform offers a powerful tool for identifying and validating novel targets that will be valuable in the development of direct anti-fibrotic therapies. Our partnership with Engitix underscores our commitment to explore innovative approaches to treat late-stage liver disease.”
Dr Gareth Hicks, Head of the GI Drug Discovery Unit at Takeda
